European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
D002986:Clinical Trials as Topic; D017277:Drug Approval; D000077560:Enfuvirtide; D005062:European Union; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage* / Q000494:pharmacology; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000494:pharmacology; D011379:Prognosis; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide